tradingkey.logo

Evolus Q2 revenue rises 4% to $69.4 mln

ReutersAug 5, 2025 8:57 PM


Overview

  • Evolus Q2 2025 global net revenue rises 4% to $69.4 mln

  • Company expects meaningful profitability in Q4 2025

  • Launch of Evolysse drives revenue growth amid U.S. market challenges


Outlook

  • Evolus expects 2025 revenue between $295 mln and $305 mln

  • Company anticipates Q4 2025 profitability and annual profitability in 2026

  • Evolus plans to launch Evolysse™ Sculpt in 2026 and Lips in 2027

  • Company targets $700 mln revenue and 20% margin by 2028


Result Drivers

  • EVOLYSSE LAUNCH - Evolysse generated $9.7 mln in Q2 2025, marking a strong debut in the filler market

  • INTERNATIONAL GROWTH - Strong international sales contributed significantly to revenue increase

  • U.S. MARKET CHALLENGES - U.S. toxin demand softened due to decreased consumer sentiment, impacting sales


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Product Revenue

$68.70 mln

Q2 Net Income

-$17.14 mln

Q2 Gross Margin

65.3%

Q2 Adjusted Gross Margin

66.5%

Q2 Gross Profit

$45.32 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Evolus Inc is $23.50, about 61.2% above its August 4 closing price of $9.11

  • The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 56 three months ago

Press Release: ID:nBw9GDP4a

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI